Huntington's
56 programs · 55 companies
Programs
56
Companies
55
Trials
61
MOAs
36
HER2EGFRiSOS1iDLL3 ADCBCMA ADCBCL-2iCAR-T CD19SGLT2iCl18.2KIF18Ai
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Phase 1 | DLL3 | ||
| JNJ-5094 | Phase 2/3 | GIP-R | ||
| LLY-8903 | Preclinical | CD47 | ||
| Doxarapivir | Phase 3 | KRASG12C | ||
| AMG-9654 | Phase 2 | GPRC5D | ||
| GIL-9779 | Phase 1 | IL-17A | ||
| HAL-996 | Phase 1/2 | BCL-2 | ||
| Mavuratamab | NDA/BLA | BET | ||
| MRU-8112 | Preclinical | PD-L1 | ||
| EDI-3618 | NDA/BLA | FXIa | ||
| 452-7432 | Phase 2 | Aβ | ||
| Zenocagene | Approved | IL-23 | ||
| JOH-IIT-455 | Approved | CDK4/6 | ||
| Ribomavacamten | Phase 3 | BTK | ||
| AGE-4274 | Phase 1 | FcRn | ||
| GRT-6331 | NDA/BLA | TROP-2 | ||
| THI-6273 | Phase 2 | CD19 | ||
| ADI-7213 | Phase 2/3 | TIM-3 | ||
| NDR-1720 | Phase 3 | PARP | ||
| BLP-8787 | Approved | TIM-3 | ||
| Datorasimod | Approved | C5 | ||
| Zoricapivasertib | Phase 3 | TYK2 | ||
| BTA-1886 | Phase 1 | FXIa | ||
| SCI-8054 | Phase 2/3 | PRMT5 | ||
| GW-1242 | Phase 1/2 | Tau | ||
| Sovafutibatinib | Phase 1 | BCL-2 | ||
| Semalemzoparlimab | Phase 3 | EGFR | ||
| AIM-9920 | Phase 2 | AuroraA | ||
| MOM-9396 | Phase 1 | RET | ||
| GLO-7885 | Phase 1 | IL-23 | ||
| Kemarelsin | Phase 1/2 | WRN | ||
| Zoribrutinib | Phase 2/3 | WRN | ||
| Teranesiran | Phase 1 | WRN | ||
| INS-9902 | Phase 1/2 | JAK2 | ||
| EVO-1057 | Phase 3 | TYK2 | ||
| Gelicilimab | Phase 3 | PD-1 | ||
| ALK-5502 | Phase 1 | PLK4 | ||
| MIR-4070 | Phase 1/2 | USP1 | ||
| Rilulucimab | NDA/BLA | PI3Kα | ||
| GNF-1172 | NDA/BLA | PRMT5 | ||
| Fixacagene | Approved | GLP-1R | ||
| PCI-3652 | Phase 1 | IL-23 | ||
| OBS-7968 | Approved | JAK2 | ||
| ORP-8634 | Phase 1/2 | KRASG12D | ||
| Riborelsin | Phase 3 | IL-23 | ||
| ITA-4515 | Phase 3 | CD47 | ||
| Gelinaritide | Phase 2 | CFTR | ||
| Mirinesiran | Preclinical | PARP | ||
| Surasertib | Phase 2 | PARP | ||
| APN-1617 | Phase 2 | PLK4 | ||
| TAT-IIT-689 | Phase 1 | FXIa | ||
| ASA-IIT-161 | Phase 3 | MDM2 | ||
| BEA-2267 | Phase 3 | DLL3 | ||
| 002-1797 | Approved | LAG-3 | ||
| STA-2404 | NDA/BLA | CDK2 | ||
| PAH-7465 | Phase 2 | CD3 |
Trials (61)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04259098 | PFE-7809 | Phase 1 | Terminated |
| NCT05977355 | Doxarapivir | Phase 3 | Active |
| NCT04063360 | AMG-9654 | Phase 2 | Not yet recr... |
| NCT06458462 | HAL-996 | Phase 1/2 | Active |
| NCT07813900 | HAL-996 | Phase 1/2 | Active |
| NCT06327591 | MRU-8112 | Preclinical | Recruiting |
| NCT07024869 | JOH-IIT-455 | Approved | Completed |
| NCT06224700 | Ribomavacamten | Phase 3 | Not yet recr... |
| NCT04636483 | THI-6273 | Phase 2 | Completed |
| NCT03657309 | THI-6273 | Phase 2 | Not yet recr... |
| NCT04991758 | ADI-7213 | Phase 2/3 | Not yet recr... |
| NCT04783581 | ADI-7213 | Phase 2/3 | Active |
| NCT05337675 | NDR-1720 | Phase 3 | Not yet recr... |
| NCT03953513 | NDR-1720 | Phase 3 | Terminated |
| NCT07706997 | NDR-1720 | Phase 3 | Completed |
| NCT05062280 | NDR-1720 | Phase 3 | Terminated |
| NCT08270395 | BLP-8787 | Approved | Active |
| NCT06998485 | BLP-8787 | Approved | Recruiting |
| NCT06203374 | BLP-8787 | Approved | Recruiting |
| NCT06191106 | Datorasimod | Approved | Active |